145. ウエスト症候群
[臨床試験数:39,薬物数:50(DrugBank:13),標的遺伝子数:27,標的パスウェイ数:24

Searched query = "West syndrome", "Infantile spasm"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04302116
(ClinicalTrials.gov)
May 18, 20205/3/2020Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile SpasmEfficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized TrialInfantile Spasm;West SyndromeDrug: Combination therapy with vigabatrin and prednisolone;Drug: Vigabatrin TabletsKullasate SakpichaisakulNULLRecruiting2 Months14 MonthsAll250N/AThailand
2NCT03876444
(ClinicalTrials.gov)
April 1, 201912/3/2019Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile SpasmsIntravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled TrialInfantile SpasmDrug: Intravenous Methylprednisolone;Drug: Oral PednisoloneSuvasini SharmaNULLRecruiting4 Months30 MonthsAll128Phase 2;Phase 3India
3NCT02299115
(ClinicalTrials.gov)
September 5, 201718/11/2014Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile SpasmsPrednisolone vs. Vigabatrin in the First-line Treatment of Infantile SpasmsInfantile SpasmsDrug: Prednisolone;Drug: VigabatrinThe Hospital for Sick ChildrenNULLWithdrawn2 Months24 MonthsAll0Phase 3Canada
4NCT01828437
(ClinicalTrials.gov)
November 20127/4/2013Addition of Pyridoxine to Prednisolone in Infantile SpasmsAddition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled TrialInfantile SpasmsDrug: Pyridoxine plus prednisolone;Drug: PrednisoloneLady Hardinge Medical CollegeNULLCompleted3 Months36 MonthsAll62Phase 3India
5NCT01575639
(ClinicalTrials.gov)
February 20129/4/2012Prednisolone in Infantile Spasms- High Dose Versus Usual DoseRandomized Trial of High Dose (4mg/kg) Versus Usual Dose (2mg/kg) Oral Prednisolone in the Treatment of Infantile Spasms.Infantile Spasms;West SyndromeDrug: Oral prednisoloneLady Hardinge Medical CollegeNULLCompleted3 Months24 MonthsBoth63Phase 3India
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-000788-27-DE
(EUCTR)
23/09/201011/06/2010International Collaborative Study of a type of epilepsy called Infantile SpasmsInternational Collaborative Infantile Spasms Study (ICISS) - ICISS Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: SABRIL
INN or Proposed INN: Vigabatrin
Trade Name: Synacthen Depot
INN or Proposed INN: Tetracosactide Acetate
Trade Name: Decortin H
INN or Proposed INN: Prednisolone
Royal United Hospital Bath NHS TrustNULLNot RecruitingFemale: yes
Male: yes
410Phase 4Australia;Germany;United Kingdom;Switzerland;New Zealand
7EUCTR2006-000788-27-GB
(EUCTR)
20/04/200606/03/2006International Collaborative Infantile Spasms Study (ICISS) - ICISSInternational Collaborative Infantile Spasms Study (ICISS) - ICISS Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.Trade Name: SABRIL SACHETS
INN or Proposed INN: Vigabatrin
Trade Name: SYNACTHEN DEPOT
INN or Proposed INN: Tetracosactide Acetate
Trade Name: SOLUBLE PREDNISOLONE TABLETS
INN or Proposed INN: Prednisolone
Royal United Hospital Bath NHS TrustNULLNot RecruitingFemale: yes
Male: yes
410Phase 4Germany;United Kingdom